Isis Pharmaceuticals CEO Unloads $2,067,061 in Stock (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) CEO Stanley Crooke sold 58,740 shares of Isis Pharmaceuticals stock on the open market in a transaction dated Friday, September 20th. The stock was sold at an average price of $35.19, for a total transaction of $2,067,060.60. Following the sale, the chief executive officer now directly owns 1,661 shares of the company’s stock, valued at approximately $58,451. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
ISIS has been the subject of a number of recent research reports. Analysts at Goldman Sachs Group Inc. reiterated a “hold” rating on shares of Isis Pharmaceuticals (NASDAQ:ISIS) in a research note to investors on Monday. They now have a $26.00 price target on the stock. Separately, analysts at Needham & Company raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) to $46.00 in a research note to investors on Monday. They now have a “positive” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $23.00 to $27.00 in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock.
Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $30.20.
Isis Pharmaceuticals (NASDAQ:ISIS) traded up 6.71% on Monday, hitting $38.48. 4,140,218 shares of the company’s stock traded hands. Isis Pharmaceuticals has a 1-year low of $7.56 and a 1-year high of $39.83. The stock has a 50-day moving average of $28.60 and a 200-day moving average of $24.24. The company’s market cap is $4.437 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.12. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $26.76 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was down 19.5% on a year-over-year basis. Analysts expect that Isis Pharmaceuticals will post $-0.56 EPS for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.